Some US Employers to Drop Coverage of GLP-1 Obesity Drugs in 2027 as Use Increases – Reuters

Some U.S. employers are planning to eliminate coverage for GLP-1 weight loss medications by 2027, according to reports from Reuters and other industry sources. This shift follows a surge in prescriptions and escalating costs that have made current pharmacy benefit models unsustainable for many corporate health plans.

Why are US employers dropping coverage for GLP-1 drugs?

The primary driver for the removal of GLP-1 coverage is the unsustainable financial pressure created by the volume of prescriptions. According to reports from Reuters and Yahoo Finance, the rapid adoption of drugs like Wegovy and Zepbound has led to a spike in healthcare spending that many employer-sponsored insurance plans cannot absorb long-term.

These medications, which mimic hormones to regulate appetite and blood sugar, are designed for chronic use. Unlike a short-term course of antibiotics, GLP-1s require ongoing administration to maintain weight loss. This creates a permanent, high-cost line item in corporate budgets. Employers are now facing a “cost cliff” where the number of eligible employees requesting the drug outweighs the projected budget increases for health benefits.

Beyond the sticker price, the sheer scale of use has disrupted the traditional predictability of pharmacy spend. According to Modern Healthcare, employers are rethinking their pharmacy benefits because the current models were not built to handle a massive percentage of a workforce utilizing a high-cost specialty drug simultaneously.

• High Per-Patient Cost: The monthly cost of these drugs remains high despite some negotiated rebates.
• Chronic Duration: The need for long-term adherence turns a monthly expense into a multi-year liability.
• Volume Surge: Increased public awareness and clinical success have driven a wave of requests that exceed initial actuarial projections.

The 2027 Timeline: Why the three-year window?

The transition toward dropping coverage by 2027 suggests a phased approach rather than an immediate cutoff. According to industry analysis, this window allows employers to manage the transition for employees currently on the medication while adjusting their financial strategies.

Many companies operate on multi-year health plan cycles. By signaling a 2027 deadline, employers can implement stricter “prior authorization” requirements in the interim. These requirements force patients to prove they have failed other weight-loss interventions—such as diet and exercise—before qualifying for the drug. This slows the rate of new enrollments while the company prepares for the eventual removal of the benefit.

Furthermore, the 2027 target aligns with expectations regarding the arrival of next-generation weight-loss drugs. Some employers are waiting to see if oral versions of these medications (pills instead of injections) will enter the market at a lower price point, which could potentially replace the expensive injectables currently in use.

How PBMs and ‘Unbundling’ Are Changing the Equation

Pharmacy Benefit Managers (PBMs) act as the middlemen between drug manufacturers, pharmacies, and employers. For years, PBMs have bundled pharmacy services into a single package. However, a report from Fierce Healthcare indicates that employers are now exploring “unbundling” these models to gain more transparency.

In a bundled model, the PBM often keeps a portion of the rebates negotiated with drug manufacturers, leaving the employer with a vague understanding of the actual cost of the drug. By unbundling, employers can separate the pharmacy benefit from other health services, allowing them to see the exact price paid for GLP-1s and the exact value of the rebates they receive.

“Employers are rethinking pharmacy benefits to gain better control over spending and transparency in how these high-cost drugs are priced and reimbursed,” according to reports from Modern Healthcare.

This shift toward transparency is making it easier for employers to identify exactly how much GLP-1s are costing them per employee, which in turn provides the data necessary to justify dropping coverage in 2027.

Public vs. Private Sector: The California Case Study

While private corporations have the autonomy to cut benefits, public entities face a different set of challenges. CalMatters has highlighted the struggle facing the state of California regarding whether it can afford to cover Ozempic and similar drugs for public employees.

Public sector health plans are often bound by collective bargaining agreements and legislative budgets. Unlike a private company that can unilaterally decide to drop a drug in 2027, a state government may face intense political backlash or legal challenges from employee unions if coverage is removed. This creates a tension between fiscal responsibility and the perceived right to healthcare for public servants.

The California situation underscores a broader trend: the “democratization” of GLP-1s. As these drugs move from niche diabetes treatments to mainstream obesity tools, the financial burden shifts from specialized clinics to general health plans. For a state government, the cost of covering these drugs for tens of thousands of employees could potentially jeopardize other public health initiatives.

This contrast suggests that while some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases – Reuters reporting focuses on corporate trends, public sector employees may find their coverage more stable but their plan premiums rising to cover the gap.

The Long-Term Health Trade-off: Cost vs. Comorbidity

The decision to drop GLP-1 coverage is fundamentally a conflict between short-term pharmacy spend and long-term healthcare savings. Obesity is a primary driver for several other expensive chronic conditions, including:

• Type 2 Diabetes: Which requires lifelong medication and monitoring.
• Cardiovascular Disease: Leading to expensive hospitalizations and surgeries.
• Sleep Apnea: Often requiring costly CPAP equipment and specialists.
• Joint Replacement: Higher rates of knee and hip replacements in obese populations.

Some health economists argue that by cutting GLP-1 coverage to save money in 2027, employers may actually increase their spending in 2030 and beyond. If employees regain the weight, the costs associated with the comorbidities listed above will return to the employer’s balance sheet. This creates a “value-based care” dilemma: do you pay for the drug now to avoid the heart attack later?

To address this, some employers are not dropping coverage entirely but are shifting to “outcome-based” coverage. In this model, the insurance continues to pay for the drug only as long as the patient meets specific weight-loss milestones. If the drug stops working or the patient fails to lose weight, coverage is terminated.

For more information on how this fits into broader health trends, see a related explainer on value-based care models.

Common Misconceptions About GLP-1 Coverage Cuts

As news of these coverage changes spreads, several misconceptions have emerged regarding why and how these drugs are being removed from plans.

Misconception 1: The drugs are being dropped because they are unsafe.

There is no evidence in the reporting from Reuters or other sources that coverage is being cut due to safety concerns. The medications remain FDA-approved for their intended uses. The motivation for the cuts is strictly financial and administrative.

Misconception 2: All employers are dropping coverage at once.

The trend is not universal. While some large employers are planning cuts for 2027, others are doubling down on coverage, viewing it as a strategic investment in employee health and productivity. The decision varies by company size, industry, and the specific PBM they employ.

Misconception 3: Employees will have no way to get the drugs.

Dropping employer coverage does not mean the drugs are unavailable. Employees can still access GLP-1s through cash-pay options, manufacturer coupons, or alternative insurance plans. However, the out-of-pocket cost—often exceeding $1,000 per month—makes this prohibitive for many.

Potential Consequences for the Workforce

The removal of GLP-1 coverage by 2027 could lead to several ripple effects across the US workforce. First, there is the risk of “medical abandonment,” where employees who have seen significant health improvements are forced to stop treatment abruptly due to cost. This can lead to rapid weight regain and a return of metabolic issues.

Second, this trend may drive employees to seek “gray market” alternatives. There has already been a rise in the use of compounded GLP-1s—versions made by pharmacies rather than the original manufacturer. While cheaper, these compounded versions may not have the same rigorous quality controls as the brand-name drugs, potentially introducing new health risks.

Finally, this could become a recruitment and retention issue. In a competitive labor market, comprehensive health benefits are a key draw. If one company provides GLP-1 coverage while another drops it, the former may have a competitive advantage in attracting talent, particularly among demographics where obesity is a prevalent health concern.

For a deeper look at how this affects employee benefits, check out a related report on corporate wellness trends.

Frequently Asked Questions

Which GLP-1 drugs are affected by these coverage changes?

The drugs most commonly affected include semaglutide (marketed as Ozempic for diabetes and Wegovy for obesity) and tirzepatide (marketed as Mounjaro for diabetes and Zepbound for obesity). These are the primary high-cost medications driving the spending surge reported by Reuters.

Why is 2027 the target date for some employers?

2027 allows companies to manage current patient populations without causing immediate disruption, while aligning with corporate budget cycles and the potential arrival of cheaper, oral versions of these medications.

Will all insurance plans stop covering weight loss drugs?

No. The decision is made at the employer level for self-insured plans. Some companies will continue coverage as a health investment, while others will cut it to manage costs. Public plans may also differ from private corporate plans.

What is “unbundling” in the context of pharmacy benefits?

Unbundling is the process of separating pharmacy benefit management (PBM) services into individual components. This allows employers to see exactly what they are paying for drugs and rebates, rather than receiving a single, bundled price from the PBM.

Can I still get GLP-1 drugs if my employer drops coverage?

Yes, but you would likely have to pay the retail price, use manufacturer assistance programs, or find a different insurance provider that offers the benefit. The cost without insurance is typically very high.

What are the alternatives to brand-name GLP-1s?

Some patients turn to compounded versions of the drugs or older, less expensive weight-loss medications. However, healthcare providers caution that compounded drugs may lack the same FDA-regulated safety and efficacy standards as brand-name versions.